Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NanoBio Corp.

This article was originally published in Start Up

Executive Summary

NanoBio is developing nanoemulsions, which might be able to combat viruses, fungi, and spores that aren't affected by other types of disinfectants.

You may also be interested in...

Eyeon Therapeutics Inc.

The founder of Eyeon Therapeutics thinks that his firm will take giant steps forward in the next six months towards commercializing an over-the-counter nanotechnology-based eye drop for treating dry eye.

One Small Step for FDA...

FDA is building a knowledge base in nanotechnology and testing its current regulatory procedures. But adapting to the new field could stress the agency's already tight resources and may damage its fragile credibility with the public.

Private Equity: One Company's Surprising Route toward Value Creation

In an unusual twist, a biotech is turning to private equity for its initial institutional financing, in the belief that it will offer a better route to long-term value creation than venture capital.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts